(VIANEWS) - Shares of Bionano Genomics (NASDAQ: BNGO) slid by a staggering 34.51% in 21 sessions from $1.13 at 2023-03-22, to $0.74 at 17:21 EST on Wednesday, after three sequential sessions in a row of losses. NASDAQ is rising 0.03% to $12,157.23, following the last session's downward trend.
Bionano Genomics's last close was $0.75, 82.75% under its 52-week high of $4.35.
About Bionano Genomics
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Bionano Genomics has a trailing twelve months EPS of $-0.36.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -45.21%.Earnings Before Interest, Taxes, Depreciation, and Amortization
Bionano Genomics's EBITDA is -7.17.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.4%, now sitting on 27.8M for the twelve trailing months.
Sales Growth
Bionano Genomics's sales growth is 24.8% for the present quarter and 24% for the next.
More news about Bionano Genomics (BNGO).